Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimorazole companion diagnostic - Azanta

Next Previous
Drug Profile

Nimorazole companion diagnostic - Azanta

Latest Information Update: 29 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Aarhus
  • Developer Azanta; European Organisation for Research and Treatment of Cancer; The Christie NHS Foundation Trust; University of Aarhus
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 29 Sep 2020 Nimorazole companion diagnostic is still in phase III trials for Head and Neck cancer (Diagnosis) in Switzerland, Netherlands, Germany and Australia (NCT01880359)
  • 16 Jul 2020 Azanta in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) and Danish Head and Neck Cancer group completes a phase III trial in Head and neck cancer (Combination therapy, Diagnosis, First-line therapy, Late-stage disease) in Australia, Belgium, France, Germany, Netherlands and Switzerland (NCT01880359)
  • 24 Mar 2020 Azanta has been acquired by Norgine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top